Table 1 General characteristics of antibiotics with activity against MRSA
Antibiotic | Route | Mechanism of action | tissue penetration (% of serum concentration) | In vitro Spectrum of activity against resistant bacteria | Dose adjustment necessary in renal impairment |
|---|---|---|---|---|---|
Linezolid | i.v., oral | bacteriostatic | 105% | MRSA, VRE | No |
Tigecycline | i.v. | bacteriostatic | 91% | MRSA, VRE, ESBL, CRB | No |
Daptomycin | i.v. | bactericidal | 68,4% | MRSA, (VRE) | No |
Vancomycin | i.v. | bactericidal | 8-10% | MRSA | Yes |
TMP-SMX | i.v., oral | bactericidal | n.a. | MRSA | Yes |
Rifampicin | i.v., oral | bactericidal | n.a. | MRSA | Yes |
Fosfomycin | i.v. | bactericidal | 91% | MRSA | Yes |
Clindamycin | i.v., oral | bacteriostatic | 95% | MRSA | No |
Quino./dalfo | i.v. | bactericidal | n.a. | MRSA, (VRE) | Yes |